Press releases

Press releases

Fugleværnsfonden and Gubra joins forces to aid local sanctuary

30 November, 2018 – Gubra has taken the next step in realizing its green vision by engaging in a five-year sponsorship of Fugleværnsfonden, which is a non-profit organization that secures and maintains nature sanctuaries across Denmark. Gubra’s donation has been earmarked for the care and protection of Gundsømagle Sø nature sanctuary near Roskilde, which is the home to many local amphibians, flowers and birds. Read more (Danish version)

JDRF and Gubra join forces to develop a new glucose responsive insulin for diabetes

18 June, 2018 – JDRF and Gubra today announced a partnership to develop a glucose-responsive insulin (GRI) as a treatment for people with insulin-requiring diabetes, such as type 1 diabetes (T1D). The Gubra approach is based on a novel, and unique concept that differs fundamentally from other glucose sensing insulin approaches and the JDRF funding commitment will help accelerate the program to its next development stage. Read more

Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments

7 September, 2017 – Today, Boehringer Ingelheim and Gubra announced a collaboration and license agreement for the development of novel peptide compounds to treat obesity. The collaboration will bring together Gubra’s expertise in the design, synthesis, characterization and in in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the development of innovative medicines for patients with cardiometabolic disease. Read more

Gubra reaches third research milestone under a collaboration agreement with Sanofi

30 August, 2017 – Today, Gubra announced the successful conclusion of a research collaboration with Sanofi, focusing on the discovery of novel gastrointestinal peptides that could potentially lead to the development of drugs for the treatment of diabetes and obesity. Read more

Gubra announces changes to executive management team

1 June, 2016 – Today, Gubra announced a change in its executive management team. In order to continue to stay focused on high scientific standards and to accommodate strong growth going forward in both its client base and revenue, Gubra has appointed CBO Henrik Blou as new CEO. In addition, Gubra has appointed Jan K. Villadsen as new CFO. Read more

Gubra announces research collaboration agreement with Sanofi to discover and develop peptide-based drugs targeting diabetes and obesity

23 September, 2013 – Gubra today announced the launch of a new research collaboration agreement with Sanofi focusing on the discovery of gut peptides in order to identify novel targets suitable for development of peptide-based drugs for treatment of people with diabetes and obesity. The new research program initiated between Gubra and Sanofi builds upon the established research consortium between Gubra, Gentofte Hospital and the University of Copenhagen partly funded by the Danish National Advanced Technology foundation. Read more

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

info@gubra.dk
+45 3152 ­2650